pancreatic cancer
Conditions
Interventions
Gold Standard:Pancreatic cancer: pancreatic ductal adenocarcinoma originating from pancreatic ductal epithelium was confirmed by pathological examination (operative biopsy, puncture biopsy, cytologica
Index test:Serum miR-25
Sponsors
The First Affiliated Hospital of the Naval Medical University of the Chinese People's Liberation Army
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients diagnosed as pancreatic cancer and chronic pancreatitis in the Department of Hepatobiliary Pancreatic and Splenic Surgery and the Department of Gastroenterology in our hospital from October 2020 to June 2022 were included in the study strictly according to the inclusion criteria. Study group: (1) 18-75 years old, male or female. (2) Pancreatic ductal adenocarcinoma originating from pancreatic ductal epithelium was confirmed by pathological examination (operative biopsy, puncture biopsy, cytological examination). Pancreatic ductal adenocarcinoma was highly suspected to be pancreatic cancer by clinical diagnosis before (pancreatic ductal adenocarcinoma, PDAC), and patients with pancreatic ductal adenocarcinoma diagnosed by surgical biopsy and blood collection before operation could be enrolled in the group. (3) before blood collection, the patient did not receive surgical treatment. (4) before blood collection, the patient had not received systematic antineoplastic drugs (Systematic Anti-tumor Therapy), including long-acting growth inhibitor analogues, interferon, PRRT (peptide receptor radionuclide therapy), mTOR inhibitors and chemotherapy, etc. (5) before blood collection, the patient did not receive radiotherapy or neoadjuvant therapy. (6) sign the informed consent form for research. Control group: (1) 18-75 years old, male or female. (2) patients who are clinically diagnosed as chronic pancreatitis and have no evidence to support the diagnosis of pancreatic cancer. (3) Blood samples were collected before admission. (4) sign the informed consent form for research.
Exclusion criteria
Exclusion criteria: (1) the subjects were in the stage of acute infection. (2) the subjects had been treated or taken drugs before blood collection. (3) failed to join the group or refused to follow up for various reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pancreatic cancer;SEN, SPE, ACC, AUC of ROC; | — |
Countries
China
Contacts
Public ContactLiu Wenyu
The First Affiliated Hospital of the Naval Medical University of the Chinese People's Liberation Army
Outcome results
None listed